LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Fundamental Analysis

NYSEARCA:LCTX • US53566P1093

1.73 USD
+0.01 (+0.58%)
Last: Feb 19, 2026, 01:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LCTX. LCTX was compared to 521 industry peers in the Biotechnology industry. While LCTX seems to be doing ok healthwise, there are quite some concerns on its profitability. LCTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • LCTX had negative earnings in the past year.
  • In the past year LCTX has reported a negative cash flow from operations.
  • In the past 5 years LCTX always reported negative net income.
  • In the past 5 years LCTX reported 4 times negative operating cash flow.
LCTX Yearly Net Income VS EBIT VS OCF VS FCFLCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • LCTX has a Return On Assets (-45.06%) which is in line with its industry peers.
  • Looking at the Return On Equity, with a value of -84.55%, LCTX is in line with its industry, outperforming 50.48% of the companies in the same industry.
Industry RankSector Rank
ROA -45.06%
ROE -84.55%
ROIC N/A
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
LCTX Yearly ROA, ROE, ROICLCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • LCTX has a Gross Margin of 97.55%. This is amongst the best in the industry. LCTX outperforms 97.31% of its industry peers.
  • LCTX's Gross Margin has improved in the last couple of years.
  • LCTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
LCTX Yearly Profit, Operating, Gross MarginsLCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • LCTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LCTX has more shares outstanding
  • The number of shares outstanding for LCTX has been increased compared to 5 years ago.
  • LCTX has a better debt/assets ratio than last year.
LCTX Yearly Shares OutstandingLCTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
LCTX Yearly Total Debt VS Total AssetsLCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • LCTX has an Altman-Z score of -1.33. This is a bad value and indicates that LCTX is not financially healthy and even has some risk of bankruptcy.
  • LCTX has a Altman-Z score (-1.33) which is comparable to the rest of the industry.
  • LCTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.00, LCTX is in line with its industry, outperforming 51.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.33
ROIC/WACCN/A
WACC8.69%
LCTX Yearly LT Debt VS Equity VS FCFLCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 4.08 indicates that LCTX has no problem at all paying its short term obligations.
  • The Current ratio of LCTX (4.08) is comparable to the rest of the industry.
  • A Quick Ratio of 4.08 indicates that LCTX has no problem at all paying its short term obligations.
  • LCTX has a Quick ratio (4.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
LCTX Yearly Current Assets VS Current LiabilitesLCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The earnings per share for LCTX have decreased strongly by -91.67% in the last year.
  • The Revenue has been growing slightly by 6.19% in the past year.
  • The Revenue has been growing by 21.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%-2.59%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.57% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 60.92% on average over the next years. This is a very strong growth
EPS Next Y-211.1%
EPS Next 2Y16.07%
EPS Next 3Y6.4%
EPS Next 5Y25.57%
Revenue Next Year19.95%
Revenue Next 2Y64.1%
Revenue Next 3Y40.48%
Revenue Next 5Y60.92%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LCTX Yearly Revenue VS EstimatesLCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
LCTX Yearly EPS VS EstimatesLCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LCTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LCTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LCTX Price Earnings VS Forward Price EarningsLCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LCTX Per share dataLCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.07%
EPS Next 3Y6.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LCTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LINEAGE CELL THERAPEUTICS IN

NYSEARCA:LCTX (2/19/2026, 1:05:46 PM)

1.73

+0.01 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-05
Inst Owners41.2%
Inst Owner Change5.02%
Ins Owners5.39%
Ins Owner Change0.51%
Market Cap398.47M
Revenue(TTM)9.50M
Net Income(TTM)-40.91M
Analysts81.54
Price Target4.25 (145.66%)
Short Float %11.63%
Short Ratio21.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-65.65%
Min EPS beat(2)-152.86%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)-22.86%
Min EPS beat(4)-152.86%
Max EPS beat(4)54.25%
EPS beat(8)5
Avg EPS beat(8)-2.23%
EPS beat(12)8
Avg EPS beat(12)3.98%
EPS beat(16)9
Avg EPS beat(16)-13.64%
Revenue beat(2)1
Avg Revenue beat(2)31.49%
Min Revenue beat(2)-21.11%
Max Revenue beat(2)84.09%
Revenue beat(4)3
Avg Revenue beat(4)98.73%
Min Revenue beat(4)-21.11%
Max Revenue beat(4)258.54%
Revenue beat(8)6
Avg Revenue beat(8)55.6%
Revenue beat(12)8
Avg Revenue beat(12)37.83%
Revenue beat(16)11
Avg Revenue beat(16)51.08%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-55.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)14.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.51
P/FCF N/A
P/OCF N/A
P/B 8.24
P/tB 66.27
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.05
BVpS0.21
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.06%
ROE -84.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.55%
FCFM N/A
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.78%
Cap/Sales 5.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z -1.33
F-Score5
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)57.88%
Cap/Sales(3y)5.42%
Cap/Sales(5y)5.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y-211.1%
EPS Next 2Y16.07%
EPS Next 3Y6.4%
EPS Next 5Y25.57%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%-2.59%
Revenue Next Year19.95%
Revenue Next 2Y64.1%
Revenue Next 3Y40.48%
Revenue Next 5Y60.92%
EBIT growth 1Y20.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.2%
EBIT Next 3Y2.48%
EBIT Next 5Y2.67%
FCF growth 1Y27.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.91%
OCF growth 3YN/A
OCF growth 5YN/A

LINEAGE CELL THERAPEUTICS IN / LCTX FAQ

What is the fundamental rating for LCTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LCTX.


What is the valuation status for LCTX stock?

ChartMill assigns a valuation rating of 0 / 10 to LINEAGE CELL THERAPEUTICS IN (LCTX). This can be considered as Overvalued.


What is the profitability of LCTX stock?

LINEAGE CELL THERAPEUTICS IN (LCTX) has a profitability rating of 2 / 10.


What is the expected EPS growth for LINEAGE CELL THERAPEUTICS IN (LCTX) stock?

The Earnings per Share (EPS) of LINEAGE CELL THERAPEUTICS IN (LCTX) is expected to decline by -211.1% in the next year.